Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer
Advanced ovarian cancer is the leading non-breast gynaecologic cause of malignant pleural effusion. Aim of this study was to assess the efficacy of mitoxantrone sclerotherapy as a palliative treatment of malignant pleural effusions due to ovarian cancer.
Sixty women with known ovarian cancer and malignant recurrent symptomatic pleural effusion were treated with chest tube drainage followed by intrapleural mitoxantrone sclerotherapy. Survival, complications and response to pleurodesis were recorded. The data are expressed as the mean ± SEM and the median.
The mean age of the entire group was 64 ± 11,24 years. The mean interval between diagnosis of ovarian cancer and presentation of the effusion was 10 ± 2,1 months. Eighteen patients (30%) had pleural effusion as the first evidence of recurrence. The mean volume of effusion drained was 1050 ± 105 ml and chest tube was removed within 4 days in 75% of patients. There were no deaths related to the procedure. Side effects of chemical pleurodesis included fever (37–38,5°C) chest pain, nausea and vomiting. At 30 days among 60 treated effusions, there was an 88% overall response rate, including 41 complete responses and 12 partial responses. At 60 days the overall response was 80% (38 complete responses and 10 partial responses). The mean survival of the entire population was 7,5 ± 1,2 months.
Mitoxantrone is effective in the treatment of malignant pleural effusion secondary to ovarian cancer without causing significant local or systemic toxicity.
- Hausheer, FH, Yarbro, JW (1985) Diagnosis and treatment of malignant pleural effusion. Semin Oncol 12: pp. 54-75
- Lynch, TJ (1993) Management of malignant pleural effusions. Chest 103: pp. 385-389
- Saffran, L, Ost, D, Fein, A, Schiff, M (2000) Outpatient pleurodesis of malignant pleural effusions using a small-bore pig tail catheter. Chest 118: pp. 417-421 CrossRef
- Dvoretsky, PM, Richards, KA, Bonfiglio, TA (1989) The pathology and behavior of ovarian cancer. Path Ann 24: pp. 1-24
- Ovary In American Joint Committee on Cancer: AJCC Cancer Staging Manual 6 Edition New York, NY: Springer 2002, 275–284.
- Statement of the American Thoracic Society: management of malignant pleural effusions Am J Respir Crit Care Med 2000, 162:1987–2001.
- Sahn, SA (1993) Pleural effusion in lung cancer. Clin Chest Med 14: pp. 189-2000
- Johnston, WW (1985) The malignant pleural effusion: a review of cytopathologic diagnosis of 584 specimens from 472 consecutive patients. Cancer 56: pp. 905-909 CrossRef
- Antunes, G, Neville, E, Duffy, J, Ali, N (2003) BTS guidelines for the management of malignant pleural effusions. Thorax 58: pp. 29-38 CrossRef
- Hausheer, FH, Yarbro, JW (1987) Diagnosis and treatment of malignant pleural effusion. Cancer Metastasis Rev 6: pp. 23-40 CrossRef
- Patz, E, McAdams, P, Erasmus, J, Goodman, P, Culhane, D, Gilkeson, R, Herndon, J (1998) Sclerotherapy for malignant pleural effusions. A prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest 113: pp. 1305-1311 CrossRef
- Seaton, KG, Patz, EF, Goodman, PC (1995) Palliative treatment of malignant pleural effusions: value of small-bore catheter thoracostomy and doxycycline sclerotherapy. Am J Roentgen 164: pp. 589-591
- Cheng D, Chan YM, Ng T, Cheung A, Ngan H, Wong LC: Mitomycin chemotherapeutic pleurodesis to palliate malignant pleural effusions secondary to gynaecological cancer. Acta Obstet Gynecol Scand 1999, 443–446.
- Hartman, DL, Gaither, JM, Kesler, KA (1993) Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 105: pp. 743-748
- Gravelyn, TR, Michelson, MK, Gross, BH (1987) Tetracycline pleurodesis for malignant pleural effusions: a 10-year retrospective study. Cancer 59: pp. 1973-1977 CrossRef
- Goff, BA, Mueller, PR, Muntz, HG (1993) Small chest tube drainage followed by bleomycin sclerosis for malignant pleural effusions. Obstet Gynecol 81: pp. 993-996
- Moffet, MJ, Ruckdeschel, JC (1992) Bleomycin and tetracycline in malignant pleural effusions: a review. Semin Oncol 19: pp. 59-63
- Ostrowski, MJ (1989) Intracavitary therapy with bleomycin for the treatment of malignant pleural effusions. J Surg Oncol 1: pp. 7-13 CrossRef
- Ruckdeschel, JC, Moores, D, Lee, JY, Einhorn, LH, Momdelbaum, I, Koeller, J, Weiss, GR, Losada, M, Koller, JH (1991) Intrapleural therapy for malignant pleural effusions: a randomised comparison of bleomycin and tetracycline. Chest 100: pp. 1528-1535 CrossRef
- Rehse, DH, Aye, RW, Florence, MG (1999) Respiratory failure following talc pleurodesis. Am J Surg 177: pp. 437-440 CrossRef
- Marom, EM, Patz, EF, Erasmus, JJ, McAdams, HP, Goodman, PC, Herndon, JE (1999) Malignant pleural effusions: treatment with small-bore catheter thoracostomy and talc pleurodesis. Radiology 210: pp. 277-281
- Fingar, BL (1992) Sclerosing agents used to control malignant pleural effusions. Hosp Pharm 27: pp. 622-628
- Vargas, FS, Teixeira, LR, Antonangelo, L, Silva, lM, Strauz, CM, Light, RW (1998) Acute and chronic pleural changes after intrapleural instillation of mitoxantrone in rabbits. Lung 176: pp. 227-236 CrossRef
- Seitzer, D, Musch, E, Kuhn, W (1990) Die locale behandlung maligner pleuraergusse bei gynakologischen tumoren. Zent Bl Gynakol 112: pp. 757-765
- Musch, E, Loos, U, Mackes, KG Intrapleural mitoxantrone in the treatment of malignant pleural effusions. In: Kreidler, H, Link, KH, Aigner, RB eds. (1988) In Advances in Regional Cancer Therapy. Karger, Basel, pp. 184-189
- Maiche, AG, Virkunnen, P, Kontkanen, T, Mokkynen, K, Porkka, K (1993) Bleomycin and mitoxantrone in the treatment of malignant pleural effusions. Am J Clin Oncol 16: pp. 50-53 CrossRef
- Van Belle, AF, Velde, GPM, Weuters, EFM (1998) Chemical pleurodesis with mitoxantrone in the management of malignant effusion. Eur J Cancer 34: pp. 206-207 CrossRef
- Morales, M, Exposito, MC (1995) Intrapleural mitoxantrone for the palliative care treatment of malignant pleural effusions. Support Care Cancer 3: pp. 147-149 CrossRef
- Groth, G, Gatzmeier, U, Haussingen, K, Heckmayr, M, Magnussen, H, Neuhauss, R, Pavel, JV (1991) Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann Oncol 2: pp. 213-215
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-684X/3/4/prepub
- Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
BMC Palliative Care
- Online Date
- September 2004
- Online ISSN
- BioMed Central
- Additional Links
- Author Affiliations
- 1. Cardiothoracic Surgery Department, Theagenio Cancer Hospital, A. Simeonidi 2, Thessaloniki, Greece
- 2. Anaesthesiology Department, Theagenio Cancer Hospital, A. Simeonidi 2, Thessaloniki, Greece
- 3. Gynaecologic Oncology Department, Theagenio Cancer Hospital, A. Simeonidi 2, Thessaloniki, Greece
- 4. Cytopathology Department, Theagenio Cancer Hospital, A. Simeonidi 2, Thessaloniki, Greece